-
1
-
-
41349099104
-
Cancer statistics, 2008
-
Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
-
(2008)
CA Cancer J Clin
, vol.58
, pp. 71-96
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
2
-
-
40949147326
-
Quality of life and satisfaction with outcome among prostate-cancer survivors
-
Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358 (2008) 1250-1261
-
(2008)
N Engl J Med
, vol.358
, pp. 1250-1261
-
-
Sanda, M.G.1
Dunn, R.L.2
Michalski, J.3
-
3
-
-
33846701592
-
Cumulative cost pattern comparison of prostate cancer treatments
-
Wilson L.S., Tesoro R., Elkin E.P., et al. Cumulative cost pattern comparison of prostate cancer treatments. Cancer 109 (2007) 518-527
-
(2007)
Cancer
, vol.109
, pp. 518-527
-
-
Wilson, L.S.1
Tesoro, R.2
Elkin, E.P.3
-
4
-
-
0034649284
-
Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines
-
Grover S.A., Dorais M., Paradis G., et al. Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. Can Med Assoc J 163 (2000) 1263-1269
-
(2000)
Can Med Assoc J
, vol.163
, pp. 1263-1269
-
-
Grover, S.A.1
Dorais, M.2
Paradis, G.3
-
5
-
-
0037126526
-
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
-
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
-
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
-
(2002)
Circulation
, vol.106
, pp. 3143-3421
-
-
-
6
-
-
39549117783
-
Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT Study
-
Rosario D.J., Lane J.A., Metcalfe C., et al. Contribution of a single repeat PSA test to prostate cancer risk assessment: experience from the ProtecT Study. Eur Urol 53 (2008) 777-784
-
(2008)
Eur Urol
, vol.53
, pp. 777-784
-
-
Rosario, D.J.1
Lane, J.A.2
Metcalfe, C.3
-
7
-
-
35648951103
-
Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL
-
Canby-Hagino E., Hernandez J., Brand T.C., et al. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL. Urology 70 (2007) 748-752
-
(2007)
Urology
, vol.70
, pp. 748-752
-
-
Canby-Hagino, E.1
Hernandez, J.2
Brand, T.C.3
-
8
-
-
0026522840
-
Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease
-
Carter H.B., Pearson J.D., Metter E.J., et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267 (1992) 2215-2220
-
(1992)
JAMA
, vol.267
, pp. 2215-2220
-
-
Carter, H.B.1
Pearson, J.D.2
Metter, E.J.3
-
9
-
-
33646459214
-
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial
-
Thompson I.M., Ankerst D.P., Chi C., et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 98 (2006) 529-534
-
(2006)
J Natl Cancer Inst
, vol.98
, pp. 529-534
-
-
Thompson, I.M.1
Ankerst, D.P.2
Chi, C.3
-
10
-
-
0028801975
-
A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer
-
Gann P.H., Hennekens C.H., and Stampfer M.J. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA 273 (1995) 289-294
-
(1995)
JAMA
, vol.273
, pp. 289-294
-
-
Gann, P.H.1
Hennekens, C.H.2
Stampfer, M.J.3
-
11
-
-
0034875454
-
Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging
-
Fang J., Metter E.J., Landis P., et al. Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging. Urology 58 (2001) 411-416
-
(2001)
Urology
, vol.58
, pp. 411-416
-
-
Fang, J.1
Metter, E.J.2
Landis, P.3
-
12
-
-
57149118824
-
Defining increased future risk for prostate cancer: evidence from a population based screening cohort
-
Schröder F.H., Roobol M.J., Andriole G.L., et al. Defining increased future risk for prostate cancer: evidence from a population based screening cohort. J Urol 181 (2009) 69-74
-
(2009)
J Urol
, vol.181
, pp. 69-74
-
-
Schröder, F.H.1
Roobol, M.J.2
Andriole, G.L.3
-
13
-
-
56649091399
-
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial
-
Grubb III R.L., Pinsky P.F., Greenlee R.T., et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int 102 (2008) 1524-1530
-
(2008)
BJU Int
, vol.102
, pp. 1524-1530
-
-
Grubb III, R.L.1
Pinsky, P.F.2
Greenlee, R.T.3
-
14
-
-
33846959137
-
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years
-
Lilja H., Ulmert D., Björk T., et al. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44-50 years. J Clin Oncol 25 (2007) 431-436
-
(2007)
J Clin Oncol
, vol.25
, pp. 431-436
-
-
Lilja, H.1
Ulmert, D.2
Björk, T.3
-
15
-
-
9644281516
-
Prostate cancer screening
-
Catalona W.J. Prostate cancer screening. BJU Int 94 (2004) 964-966
-
(2004)
BJU Int
, vol.94
, pp. 964-966
-
-
Catalona, W.J.1
-
16
-
-
64349116427
-
-
Poster 589:, May 17-22, Orlando, FL
-
Lilja H, Cronin A, Scardino P, et al. Poster 589: a single PSA predicts prostate cancer up to 30 years subsequently, even in men below age 40. Presented at the Annual Meeting of the American Urological Association, May 17-22, 2008, Orlando, FL.
-
(2008)
a single PSA predicts prostate cancer up to 30 years subsequently, even in men below age 40. Presented at the Annual Meeting of the American Urological Association
-
-
Lilja, H.1
Cronin, A.2
Scardino, P.3
-
17
-
-
35348823195
-
The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy
-
Vickers A.J., Ulmert D., Serio A.M., et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 121 (2007) 2212-2217
-
(2007)
Int J Cancer
, vol.121
, pp. 2212-2217
-
-
Vickers, A.J.1
Ulmert, D.2
Serio, A.M.3
-
18
-
-
41149091657
-
Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study
-
Ulmert D., Cronin A.M., Bjork T., et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6 (2008) 6-13
-
(2008)
BMC Med
, vol.6
, pp. 6-13
-
-
Ulmert, D.1
Cronin, A.M.2
Bjork, T.3
-
19
-
-
2442715038
-
Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter
-
Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med 350 (2004) 2239-2246
-
(2004)
N Engl J Med
, vol.350
, pp. 2239-2246
-
-
Thompson, I.M.1
Pauler, D.K.2
Goodman, P.J.3
-
20
-
-
33645648583
-
Viewpoint: expanding prostate cancer screening
-
Catalona W.J., Loeb S., and Han M. Viewpoint: expanding prostate cancer screening. Ann Intern Med 144 (2006) 441-443
-
(2006)
Ann Intern Med
, vol.144
, pp. 441-443
-
-
Catalona, W.J.1
Loeb, S.2
Han, M.3
-
21
-
-
51549117737
-
-
Accessed May 30, 2008
-
Ries L., Melbert D., Drapcho M., et al. SEER cancer statistics review. Based on November 2007 SEER data submission, posted to SEER Web site (2008). http://seer.cancer.gov/csr/1975_2005/ Accessed May 30, 2008
-
(2008)
SEER cancer statistics review. Based on November 2007 SEER data submission, posted to SEER Web site
-
-
Ries, L.1
Melbert, D.2
Drapcho, M.3
-
22
-
-
0027211001
-
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer
-
Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
-
(1993)
J Urol
, vol.150
, pp. 110-114
-
-
Partin, A.W.1
Yoo, J.2
Carter, H.B.3
-
23
-
-
8444251062
-
Prostate-specific antigen (PSA) best practice policy
-
American Urological Association (AUA)
-
American Urological Association (AUA). Prostate-specific antigen (PSA) best practice policy. Oncology (Williston Park) 4 (2000) 267-280
-
(2000)
Oncology (Williston Park)
, vol.4
, pp. 267-280
-
-
-
24
-
-
0029830551
-
Age-specific reference ranges for prostate-specific antigen in black men
-
Morgan T.O., Jacobsen S.J., McCarthy W.F., et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med 335 (1996) 304-310
-
(1996)
N Engl J Med
, vol.335
, pp. 304-310
-
-
Morgan, T.O.1
Jacobsen, S.J.2
McCarthy, W.F.3
-
25
-
-
33846525375
-
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL
-
Al-Azab R., Toi A., Lockwood G., et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology 69 (2007) 103-107
-
(2007)
Urology
, vol.69
, pp. 103-107
-
-
Al-Azab, R.1
Toi, A.2
Lockwood, G.3
-
26
-
-
36349014841
-
Prostate volume and adverse prostate cancer features: fact not artifact
-
Briganti A., Chun F.K., Suardi N., et al. Prostate volume and adverse prostate cancer features: fact not artifact. Eur J Cancer 43 (2007) 2669-2677
-
(2007)
Eur J Cancer
, vol.43
, pp. 2669-2677
-
-
Briganti, A.1
Chun, F.K.2
Suardi, N.3
-
27
-
-
35648943184
-
High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates
-
Sajadi K.P., Kim T., Terris M.K., et al. High yield of saturation prostate biopsy for patients with previous negative biopsies and small prostates. Urology 70 (2007) 691-695
-
(2007)
Urology
, vol.70
, pp. 691-695
-
-
Sajadi, K.P.1
Kim, T.2
Terris, M.K.3
-
28
-
-
55649123911
-
PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging
-
Loeb S., Kettermann A., Ferrucci L., et al. PSA doubling time versus PSA velocity to predict high-risk prostate cancer: data from the Baltimore Longitudinal Study of Aging. Eur Urol 54 (2008) 1073-1080
-
(2008)
Eur Urol
, vol.54
, pp. 1073-1080
-
-
Loeb, S.1
Kettermann, A.2
Ferrucci, L.3
-
29
-
-
51649101380
-
Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era
-
Chen Y.C., Page J.H., Chen R., et al. Family history of prostate and breast cancer and the risk of prostate cancer in the PSA era. Prostate 68 (2008) 1582-1591
-
(2008)
Prostate
, vol.68
, pp. 1582-1591
-
-
Chen, Y.C.1
Page, J.H.2
Chen, R.3
-
30
-
-
0034644185
-
Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland
-
Lichtenstein P., Holm N.V., Verkasalo P.K., et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343 (2000) 78-85
-
(2000)
N Engl J Med
, vol.343
, pp. 78-85
-
-
Lichtenstein, P.1
Holm, N.V.2
Verkasalo, P.K.3
-
31
-
-
40049098166
-
Cumulative association of five genetic variants with prostate cancer
-
Zheng S.L., Sun J., Wiklund F., et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358 (2008) 910-919
-
(2008)
N Engl J Med
, vol.358
, pp. 910-919
-
-
Zheng, S.L.1
Sun, J.2
Wiklund, F.3
-
32
-
-
50249119780
-
Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations
-
Sun J., Chang B.L., Isaacs S.D., et al. Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. Prostate 68 (2008) 1257-1262
-
(2008)
Prostate
, vol.68
, pp. 1257-1262
-
-
Sun, J.1
Chang, B.L.2
Isaacs, S.D.3
-
33
-
-
34247482327
-
Multiple regions within 8q24 independently affect risk for prostate cancer
-
Haiman C.A., Patterson N., Freedman M.L., et al. Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39 (2007) 638-644
-
(2007)
Nat Genet
, vol.39
, pp. 638-644
-
-
Haiman, C.A.1
Patterson, N.2
Freedman, M.L.3
-
34
-
-
0036783557
-
Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels
-
Lefkowitz G.K., Taneja S.S., Brown J., et al. Follow up interval prostate biopsy 3 years after diagnosis of high grade prostatic intraepithelial neoplasia is associated with high likelihood of prostate cancer, independent of change in prostate specific antigen levels. J Urol 168 4 Pt. 1 (2002) 1415-1418
-
(2002)
J Urol
, vol.168
, Issue.4 PART 1
, pp. 1415-1418
-
-
Lefkowitz, G.K.1
Taneja, S.S.2
Brown, J.3
-
35
-
-
0029045030
-
Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate
-
Keetch D.W., Humphrey P., Stahl D., et al. Morphometric analysis and clinical follow up of isolated prostatic intraepithelial neoplasia in needle biopsy of the prostate. J Urol 154 2 Pt. 1 (1995) 347-351
-
(1995)
J Urol
, vol.154
, Issue.2 PART 1
, pp. 347-351
-
-
Keetch, D.W.1
Humphrey, P.2
Stahl, D.3
-
37
-
-
0028902318
-
Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer
-
Ivanovic V., Melman A., vis-Joseph B., et al. Elevated plasma levels of TGF-β1 in patients with invasive prostate cancer. Nat Med 1 (1995) 282-284
-
(1995)
Nat Med
, vol.1
, pp. 282-284
-
-
Ivanovic, V.1
Melman, A.2
vis-Joseph, B.3
-
38
-
-
0031019319
-
Transforming growth factor beta as a clinical biomarker for prostate cancer
-
Perry K.T., Anthony C.T., Case T., et al. Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49 (1997) 151-155
-
(1997)
Urology
, vol.49
, pp. 151-155
-
-
Perry, K.T.1
Anthony, C.T.2
Case, T.3
-
39
-
-
0001693183
-
Serum concentrations of transforming growth factor-β1 in patients with benign and malignant prostatic diseases
-
Wolff J.M., Fandel T.H., Borchers H., et al. Serum concentrations of transforming growth factor-β1 in patients with benign and malignant prostatic diseases. Anticancer Res 19 suppl 4A (1999) 2657-2659
-
(1999)
Anticancer Res
, vol.19
, Issue.SUPPL. 4A
, pp. 2657-2659
-
-
Wolff, J.M.1
Fandel, T.H.2
Borchers, H.3
-
40
-
-
3042823539
-
Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer
-
Michalaki V., Syrigos K., Charles P., et al. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 90 (2004) 2312-2316
-
(2004)
Br J Cancer
, vol.90
, pp. 2312-2316
-
-
Michalaki, V.1
Syrigos, K.2
Charles, P.3
-
41
-
-
0033911711
-
Serum interleukin 6 as a prognostic factor in patients with prostate cancer
-
Nakashima J., Tachibana M., Horiguchi Y., et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. Clin Cancer Res 6 (2000) 2702-2706
-
(2000)
Clin Cancer Res
, vol.6
, pp. 2702-2706
-
-
Nakashima, J.1
Tachibana, M.2
Horiguchi, Y.3
-
42
-
-
41749088455
-
PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance
-
Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: Implication in selecting candidates for active surveillance. J Urol 179 (2008) 1804-1809
-
(2008)
J Urol
, vol.179
, pp. 1804-1809
-
-
Nakanishi, H.1
Groskopf, J.2
Fritsche, H.A.3
-
43
-
-
55649120679
-
Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy
-
Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 54 (2008) 1081-1088
-
(2008)
Eur Urol
, vol.54
, pp. 1081-1088
-
-
Haese, A.1
de la Taille, A.2
van Poppel, H.3
-
44
-
-
35148826768
-
Prostate cancer risk assessment program: a 10-year update of cancer detection
-
Giri V.N., Beebe-Dimmer J., Buyyounouski M., et al. Prostate cancer risk assessment program: a 10-year update of cancer detection. J Urol 178 (2007) 1920-1924
-
(2007)
J Urol
, vol.178
, pp. 1920-1924
-
-
Giri, V.N.1
Beebe-Dimmer, J.2
Buyyounouski, M.3
-
45
-
-
25144445294
-
BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian
-
Friedenson B. BRCA1 and BRCA2 pathways and the risk of cancers other than breast or ovarian. MedGenMed 7 (2005) 60
-
(2005)
MedGenMed
, vol.7
, pp. 60
-
-
Friedenson, B.1
-
46
-
-
2442440933
-
BRCA mutations and risk of prostate cancer in Ashkenazi Jews
-
Kirchhoff T., Kauff N.D., and Mitra N. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res 10 (2004) 2918-2921
-
(2004)
Clin Cancer Res
, vol.10
, pp. 2918-2921
-
-
Kirchhoff, T.1
Kauff, N.D.2
Mitra, N.3
-
47
-
-
34147136783
-
EPCA-2: a highly specific serum marker for prostate cancer
-
Leman E.S., Cannon G.W., Trock B.J., et al. EPCA-2: a highly specific serum marker for prostate cancer. Urology 69 (2007) 714-720
-
(2007)
Urology
, vol.69
, pp. 714-720
-
-
Leman, E.S.1
Cannon, G.W.2
Trock, B.J.3
-
48
-
-
64349089205
-
Analysis of a second EPCA-2 epitope as a serum test for prostate cancer (abstract)
-
Leman E., Magheli A., and Cannon G.W. Analysis of a second EPCA-2 epitope as a serum test for prostate cancer (abstract). J Urol 179 (2008) 704
-
(2008)
J Urol
, vol.179
, pp. 704
-
-
Leman, E.1
Magheli, A.2
Cannon, G.W.3
|